0001415397
2026-01-01
2026-06-30
0001415397
2026-08-14
0001415397
2026-06-30
0001415397
2025-12-31
0001415397
us-gaap:RelatedPartyMember
2026-06-30
0001415397
us-gaap:RelatedPartyMember
2025-12-31
0001415397
2025-01-01
2025-06-30
0001415397
2026-04-01
2026-06-30
0001415397
2025-04-01
2025-06-30
0001415397
us-gaap:CommonStockMember
2024-12-31
0001415397
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0001415397
us-gaap:RetainedEarningsMember
2024-12-31
0001415397
2024-12-31
0001415397
us-gaap:CommonStockMember
2025-01-01
2025-03-31
0001415397
us-gaap:AdditionalPaidInCapitalMember
2025-01-01
2025-03-31
0001415397
us-gaap:RetainedEarningsMember
2025-01-01
2025-03-31
0001415397
2025-01-01
2025-03-31
0001415397
us-gaap:CommonStockMember
2025-03-31
0001415397
us-gaap:AdditionalPaidInCapitalMember
2025-03-31
0001415397
us-gaap:RetainedEarningsMember
2025-03-31
0001415397
2025-03-31
0001415397
us-gaap:AdditionalPaidInCapitalMember
2025-04-01
2025-06-30
0001415397
us-gaap:RetainedEarningsMember
2025-04-01
2025-06-30
0001415397
us-gaap:CommonStockMember
2025-04-01
2025-06-30
0001415397
us-gaap:CommonStockMember
2025-06-30
0001415397
us-gaap:AdditionalPaidInCapitalMember
2025-06-30
0001415397
us-gaap:RetainedEarningsMember
2025-06-30
0001415397
2025-06-30
0001415397
us-gaap:CommonStockMember
2025-12-31
0001415397
us-gaap:AdditionalPaidInCapitalMember
2025-12-31
0001415397
us-gaap:RetainedEarningsMember
2025-12-31
0001415397
us-gaap:CommonStockMember
2026-01-01
2026-03-31
0001415397
us-gaap:AdditionalPaidInCapitalMember
2026-01-01
2026-03-31
0001415397
us-gaap:RetainedEarningsMember
2026-01-01
2026-03-31
0001415397
2026-01-01
2026-03-31
0001415397
us-gaap:CommonStockMember
2026-03-31
0001415397
us-gaap:AdditionalPaidInCapitalMember
2026-03-31
0001415397
us-gaap:RetainedEarningsMember
2026-03-31
0001415397
2026-03-31
0001415397
us-gaap:CommonStockMember
2026-04-01
2026-06-30
0001415397
us-gaap:AdditionalPaidInCapitalMember
2026-04-01
2026-06-30
0001415397
us-gaap:RetainedEarningsMember
2026-04-01
2026-06-30
0001415397
us-gaap:CommonStockMember
2026-06-30
0001415397
us-gaap:AdditionalPaidInCapitalMember
2026-06-30
0001415397
us-gaap:RetainedEarningsMember
2026-06-30
0001415397
2020-10-08
0001415397
2020-10-08
2020-10-08
0001415397
2021-05-14
2021-05-14
0001415397
us-gaap:CommonStockMember
2021-05-14
2021-05-14
0001415397
2021-05-14
0001415397
raph:PayablesToRelatedPartyOfficersMember
2026-06-30
0001415397
raph:PayablesToRelatedPartyOfficersMember
2025-12-31
0001415397
raph:ShorttermCreditFromRelatedPartyMember
2026-06-30
0001415397
raph:ShorttermCreditFromRelatedPartyMember
2025-12-31
0001415397
raph:ConsultingServicesMember
2026-01-01
2026-06-30
0001415397
raph:ConsultingServicesMember
2025-01-01
2025-06-30
0001415397
raph:StockbasedCompensationMember
2026-01-01
2026-06-30
0001415397
raph:StockbasedCompensationMember
2025-01-01
2025-06-30
0001415397
raph:CFOFeeMember
2026-01-01
2026-06-30
0001415397
raph:CFOFeeMember
2025-01-01
2025-06-30
shares
iso4217:USD
iso4217:USD
shares
pure
10-Q
true
2026-06-30
2026
false
000-53002
Raphael Pharmaceutical Inc.
NV
26-0204284
4 Lui Paster Street
Tel Aviv-Jaffa
IL
6803605
(+972)
52-775-5072
true
Yes
Yes
Non-accelerated Filer
true
false
false
20176418
1000
45000
5000
6000
6000
51000
1000
2000
7000
53000
43000
34000
539000
506000
1310000
946000
1892000
1486000
0.01
0.01
50000000
21020560
20176418
20176418
20176418
20176418
202000
202000
8533000
8533000
-10620000
-10168000
-1885000
-1433000
7000
53000
77000
213000
40000
141000
345000
527000
159000
174000
-422000
-740000
-199000
-315000
-30000
-11000
-24000
-7000
-452000
-751000
-223000
-322000
0.02
0.02
0.04
0.04
0.01
0.01
0.02
0.02
20176418
20176418
19370534
19370534
20176418
20176418
19626418
19626418
18701418
187000
7960000
-8889000
-742000
575000
6000
234000
240000
350000
3000
194000
197000
-429000
-429000
19626418
196000
8388000
-9318000
-734000
8000
8000
-322000
-322000
19626418
196000
8396000
-9640000
-1048000
20176418
202000
8533000
-10168000
-1433000
-229000
-229000
20176418
202000
8533000
-10397000
-1662000
-223000
-223000
20176418
202000
8533000
-10620000
-1885000
-452000
-751000
205000
9000
1000
-1000
2000
364000
336000
33000
-27000
-44000
-239000
240000
240000
-44000
1000
45000
19000
1000
20000
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>NOTE
1:- GENERAL</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-size: 10pt">a.</span></td> <td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Raphael
Pharmaceutical Inc (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on
May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021. The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding common stock into one share of common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, Raphael and the Company completed the Share Exchange pursuant to which 9,459,253 common stock were issued to the shareholders of Raphael so that they became the holders of 90% of the issued and outstanding common stock of the Company immediately after the Share Exchange while the Company’s shareholders held, following the Share Exchange, 1,051,028 common stock which represents 10% of the Company. On May 19, 2021, as agreed by the parties to the Share Exchange, the Company changed its name to Raphael Pharmaceutical Inc. Following such Share Exchange, Raphael’s activities are the sole activities of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company’s common stock began public trading on the over-the-counter market in the U.S. in January 2023 under the symbol “RAPH”.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Going concern and management plans</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The accompanying financial statements have been
prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of
business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials,
and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the
Company’s future operating losses and the timing of becoming profitable are uncertain. As of June 30, 2026, the Company’s
accumulated deficit was $10,620. The Company has funded its operations to date primarily through equity financing and the issuance of
a loan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Additional funding will be required to complete
the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts
of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Management’s plans include, but
are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional
financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or
at all.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Management expects that the Company
will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result
in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability
to continue as a going concern exists in the event that additional funding does not occur. If such sufficient financing is not received
timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and
would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy
protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.</p>
0.90
0.90
0.10
the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock
The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding common stock into one share of common stock.
9459253
0.90
0.90
1051028
0.10
-10620000
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>NOTE
2:- SIGNIFICANT ACCOUNTING POLICIES</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">These unaudited interim financial statements
should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2025. The significant
accounting policies applied in the annual financial statements of the Company as of December 31, 2025, are applied consistently in these
interim financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>NOTE
3:- UNAUDITED INTERIM FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The accompanying unaudited condensed
consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”)
for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation
S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting
only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial
statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Operating
results for the six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the year ending
December 31, 2026.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>NOTE
4:- SHAREHOLDERS’ EQUITY</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the first and the second quarters
of 2026, there were no new issuances of common stock, warrants or share-based compensation. As of June 30, 2026, the Company had 50,000,000
authorized shares of common stock, compared with 21,020,560 authorized shares as of December 31, 2025.</p>
50000000
21020560
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>NOTE
5:- RELATED PARTY BALANCES AND TRANSACTIONS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p>
<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"> </td>
<td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>A.</b></span></td>
<td style="text-align: justify"><span style="font-size: 10pt"><b>Balances</b></span></td></tr>
</table>
<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The following related party payables are
included in accounts payable and accrued expenses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p>
<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold"> </td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">As of<br/> June 30,</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">As of <br/> December 31,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Audited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Payables to related party - Officers (*)</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,310</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">946</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Short-term credit from related party (**)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.35in"><span style="font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Relates to Chief Executive Officer’s (“CEO”),Chief Financial Officer’s (“CFO”), and Chief Technology Officer’s services and payments on behalf of the Company.</span></td></tr> </table>
<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: justify">(**)</td><td style="text-align: justify">Relates to a director. The director was appointed during the
first quarter of 2025.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company’s CEO and CFO are guarantees for the repayment of
the loan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>B.</b></span></td> <td><span style="font-size: 10pt"><b>Transactions</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended<br/>
June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Consulting services</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">192</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Stock-based compensation</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">205</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">CFO fee</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">541</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The following related party payables are
included in accounts payable and accrued expenses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p>
<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold"> </td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">As of<br/> June 30,</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">As of <br/> December 31,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Audited)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Payables to related party - Officers (*)</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,310</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">946</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Short-term credit from related party (**)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.35in"><span style="font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Relates to Chief Executive Officer’s (“CEO”),Chief Financial Officer’s (“CFO”), and Chief Technology Officer’s services and payments on behalf of the Company.</span></td></tr> </table>
<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: justify">(**)</td><td style="text-align: justify">Relates to a director. The director was appointed during the
first quarter of 2025.</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>B.</b></span></td> <td><span style="font-size: 10pt"><b>Transactions</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended<br/>
June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Consulting services</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">192</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Stock-based compensation</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">205</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">CFO fee</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">541</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>
1310000
946000
43000
34000
192000
264000
205000
72000
72000
264000
541000
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>NOTE
6:- SUBSEQUENT EVENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-indent: 0in; text-align: justify">In
accordance with ASC 855-10, the Company’s management reviewed all material events through the date of these consolidated financial
statements. Effective July 16, 2026, Guy Ofir resigned from his positions as Chief Financial Officer, General Counsel and Director of
the Company, and Uri Tadelis was appointed Chief Financial Officer. These changes were reported by the Company on Form 8-K. Except for
the foregoing, management determined that there are no additional material subsequent events to report.</p>
false
false
false
false
None
0001415397
false
Q2
--12-31